<DOC>
	<DOCNO>NCT02962739</DOCNO>
	<brief_summary>Adherence daily dose important well Emtricitabine/Tenofovir Alafenamide ( F/TAF ) work treatment chronic HIV , prevention HIV acquisition . Methods measure medication adherence Tenofovir disoproxil fumarate ( tenofovir DF , TDF ) , similar different prodrug tenofovir , develop extrapolate F-TAF . By measure F-TAF ( drug ) metabolites blood cell dry blood spot , study plan see result predict adherence take drug . The goal study vary amount F-TAF dosing see drug level dry blood spot ( DBS ) change predictable way . This study mimic different level adherence ( 33 % , 67 % , 100 % daily dosing ) use directly observe therapy ( DOT ) establish relationship F-TAF dry blood spot adherence . Investigators also measure drug hair clipping see hair DBS better predictor adherence .</brief_summary>
	<brief_title>The Cellular Pharmacology F-TAF Dried Blood Spots</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Ambulatory 1859 year old adult . Enrollment proceed without need meet specific race/gender target , balance gender AfricanAmericans Latino representation seek . 2 . Ability comply study procedure , include directly observe dose visit availability use video stream technology . 1 . Inability give inform consent 2 . Pregnancy plan become pregnant next 12 month unwillingness use birth control 3 . Current breastfeed 4 . High risk HIV1 infection , example : sexually active HIV infect partner ; men sex men may engage condomless intercourse HIVinfected partner , partner unknown status study ; male females exchange sex money , shelter , gift ; active injection drug use last 12 month ; newly diagnose sexually transmit infection last 6 month 5 . Positive screen HIV+ ELISA suspect acute HIV infection opinion clinician . Example sign symptom acute HIV infection include combination : fever , headache , fatigue , arthralgia , vomit , myalgia , . diarrhea , pharyngitis , rash , night sweat , adenopathy ( cervical inguinal ) 6 . Positive Hepatitis B Virus ( HBV ) surface antigen test screen 7 . Active psychiatric illness , social condition , alcohol/drug abuse , opinion investigator , would interfere study requirement . 8 . Glomerular Filtration Rate ( GFR ) estimate &lt; 60 ml/min ( MDRD equation ) . 9 . Urine dipstick protein ≥ 2+ 10 . Total bilirubin and/or hepatic transaminase ( ALT AST ) ≥ 2.5x upper limit normal 11 . Absolute neutrophil count ≤ 1,500/mm3 , platelet count ≤ 100,000/mm3 , hemoglobin ≤ 10 g/dL . 12 . Symptomatic hemoglobinopathy active hemolysis . 13 . History pathological , nontraumatic bone fracture 14 . Any laboratory value uncontrolled medical condition , opinion investigator , would interfere study condition , heart disease and/or cancer . 15 . Prohibited concomitant medication : investigational agent ( within 30 day enrollment ) , aminoglycosides , ganciclovir/valganciclovir , chronic highdose acyclovir/valacyclovir ( &gt; 800mg acyclovir &gt; 500mg valacyclovir 7 day ) , cyclosporine , amphotericin B , foscarnet , cidofovir , product similar active ingredient study medication include TRUVADA® , ATRIPLA® , COMPLERA® , EMTRIVA® , VIREAD® ; drug contain lamivudine adefovir , close analog FTC tenofovir , respectively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>